Document is current

Article History

Received: 17 September 2024

Accepted: 28 November 2024

First Online: 20 December 2024

Declarations

:

: This study is conducted according to the Management Policy of the MHI Hospital Cohort and is approved by the Management Committee of the Biobank as well as the Scientific and Ethics committees of the MHI.

: All patients agreed to participate in the Hospital Cohort and signed a consent form.

: Not applicable (see Ethics approval and Consent to participate).

: S. de Denus reports grants outside the submitted work from AstraZeneca and RMS/Dalcor. M.-P. Dubé has a minor equity interest in DalCor Pharmaceuticals. J.-C. Tardif has received research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio, and Sanofi; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, and Pendopharm; and minor equity interest in DalCor Pharmaceuticals. M.-P. Dubé and J.-C. Tardif are authors on the following patents without royalties received: “Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events,” “Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent,” and “Methods for using low dose colchicine after myocardial infarction.”